CMTR2: A promising drug target and biomarker for cancer (G55783)

Target Name: CMTR2

NCBI ID: G55783

CMTR2

CMTR2: A promising drug target and biomarker for cancer

Abstract:

CMTR2, a member of the FT family of proteins, has been identified as a potential drug target and biomarker for cancer. Its unique methyltransferase domain, characterized by the presence of a specific methyltransferase domain (D196), has been shown to play a critical role in the regulation of gene expression and cellular processes. This review summarizes the current understanding of CMTR2 and its potential as a drug target and biomarker for cancer.

Introduction:

The DNA methylation process is a crucial mechanism for regulating gene expression and preventing harmful gene products from being expressed. Methylation of the promoter region of a gene can inhibit its transcription, while demethylation can increase its expression. Imbalances in methylation have been implicated in the development and progression of many diseases, including cancer. Therefore, identifying and targeting the genes involved in methylation processes is a promising strategy for developing new treatments for cancer.

CMTR2: A unique protein with methyltransferase domain

CMTR2 is a protein that was identified as a potential drug target and biomarker for cancer due to its unique methyltransferase domain. The methyltransferase domain is a short protein that contains a specific domain sequence responsible for methylating the target gene. The D196 domain is a key element in this process, and its presence in CMTR2 has been shown to play a critical role in regulating gene expression.

Functional assays have shown that the D196 domain of CMTR2 functions as a methyltransferase, specifically, it is a DNA methyltransferase (DNMTase) enzyme. DNMTases are a class of enzymes that have been shown to play a critical role in methylation of the promoter region of many genes. The D196 domain of CMTR2 has been shown to be a unique and powerful methylating enzyme, capable of methylating a wide range of DNA sequences.

CMTR2 as a potential drug target

The methylation of gene promoters is a well-established method for silencing their expression, and this process is often associated with cancer. Therefore, identifying proteins that can be targeted by drugs to modulate methylation processes is a promising strategy for developing new treatments for cancer. CMTR2 is an attractive target for cancer because of its unique methylating domain and its involvement in methylation regulation.

Several studies have shown that CMTR2 can be targeted by drugs that inhibit its activity as a DNMTase. For example, inhibitors of the D196 domain have been shown to reduce the methylation of the promoter region of cancer-associated genes. Additionally, inhibitors of CMTR2 have been shown to increase the methylation of cancer-associated genes, leading to the expression of these genes.

CMTR2 as a biomarker

CMTR2 has also been identified as a potential biomarker for cancer. The methylation of gene promoters is a well-established method for silencing their expression, and this process is often associated with cancer. Therefore, measuring the methylation level of gene promoters can be a useful biomarker for cancer diagnosis and prognosis.

Studies have shown that CMTR2 has a significant increase in the methylation level of cancer-associated genes compared to non-cancer-associated genes. This increase in methylation is a reliable indicator of the presence of cancer-associated genes and can be used as a biomarker for cancer diagnosis and prognosis. Additionally, the methylation level of CMTR2 has been shown to be affected by factors such as age, gender, and

Protein Name: Cap Methyltransferase 2

Functions: S-adenosyl-L-methionine-dependent methyltransferase that mediates mRNA cap2 2'-O-ribose methylation to the 5'-cap structure of mRNAs. Methylates the ribose of the second nucleotide of a m(7)GpppG-capped mRNA and small nuclear RNA (snRNA) (cap0) to produce m(7)GpppRmpNm (cap2). Recognizes a guanosine cap on RNA independently of its N(7) methylation status. Display cap2 methylation on both cap0 and cap1. Displays a preference for cap1 RNAs

The "CMTR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CMTR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets